S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
Log in
(Ad)
Located just 25 miles from Cleveland... is a supergreenhouse unlike anything we've ever seen. Listed at over 1.4 million sq ft, (the size of 9 full-sized Costco warehouses), this marijuana grow house is capable of producing over 341,000 pounds of weed/year! And very soon it will come online and could turn a tiny 60-cent pot company into the dominator in the white-hot weed market.

NASDAQ:SBPH - Spring Bank Pharmaceuticals Stock Price, Forecast & News

$1.84
-0.03 (-1.60 %)
(As of 01/20/2020 11:17 AM ET)
Today's Range
$1.72
Now: $1.84
$2.00
50-Day Range
$1.21
MA: $2.70
$4.39
52-Week Range
$1.17
Now: $1.84
$11.32
Volume522,799 shs
Average Volume770,379 shs
Market Capitalization$30.32 million
P/E RatioN/A
Dividend YieldN/A
Beta0.48
Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of viral infections, inflammatory diseases, and various cancers using small molecule nucleotide platform. Its lead product candidate is inarigivir soproxil for the treatment of chronic hepatitis B virus (HBV). The company is also developing STimulator of INterferon Genes agonist product candidate, including SB 11285, an immunotherapeutic agent for the potential treatment of selected cancers. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SBPH
CUSIPN/A
Phone508-473-5993

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.40 per share

Profitability

Net Income$-22,850,000.00

Miscellaneous

Employees29
Market Cap$30.32 million
Next Earnings Date3/9/2020 (Estimated)
OptionableNot Optionable

Receive SBPH News and Ratings via Email

Sign-up to receive the latest news and ratings for SBPH and its competitors with MarketBeat's FREE daily newsletter.


(Ad)


Join a small community of investors looking for the next big winner. Every Sunday reveals 3 compelling stocks that should be on your radar for the week ahead. Sign up here to see what stocks have made it to our watchlist this week.

Spring Bank Pharmaceuticals (NASDAQ:SBPH) Frequently Asked Questions

What is Spring Bank Pharmaceuticals' stock symbol?

Spring Bank Pharmaceuticals trades on the NASDAQ under the ticker symbol "SBPH."

How were Spring Bank Pharmaceuticals' earnings last quarter?

Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) released its earnings results on Thursday, November, 7th. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.19. View Spring Bank Pharmaceuticals' Earnings History.

When is Spring Bank Pharmaceuticals' next earnings date?

Spring Bank Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Spring Bank Pharmaceuticals.

What price target have analysts set for SBPH?

5 brokerages have issued twelve-month target prices for Spring Bank Pharmaceuticals' stock. Their forecasts range from $1.70 to $29.00. On average, they expect Spring Bank Pharmaceuticals' stock price to reach $14.43 in the next year. This suggests a possible upside of 684.0% from the stock's current price. View Analyst Price Targets for Spring Bank Pharmaceuticals.

What is the consensus analysts' recommendation for Spring Bank Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spring Bank Pharmaceuticals in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Spring Bank Pharmaceuticals.

Has Spring Bank Pharmaceuticals been receiving favorable news coverage?

News coverage about SBPH stock has trended positive this week, InfoTrie reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Spring Bank Pharmaceuticals earned a news impact score of 3.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Spring Bank Pharmaceuticals.

Are investors shorting Spring Bank Pharmaceuticals?

Spring Bank Pharmaceuticals saw a drop in short interest during the month of December. As of December 31st, there was short interest totalling 24,300 shares, a drop of 9.0% from the December 15th total of 26,700 shares. Based on an average daily trading volume, of 242,600 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.2% of the shares of the stock are short sold. View Spring Bank Pharmaceuticals' Current Options Chain.

Who are some of Spring Bank Pharmaceuticals' key competitors?

What other stocks do shareholders of Spring Bank Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spring Bank Pharmaceuticals investors own include Intelsat (I), Fossil Group (FOSL), AMC Entertainment (AMC), Bank of America (BAC), Associated British Foods (ABF), Chaarat Gold (CGH), Apollo Global Management (APO), China Unicom (Hong Kong) (CHU), Ciena (CIEN) and First Data (FDC).

Who are Spring Bank Pharmaceuticals' key executives?

Spring Bank Pharmaceuticals' management team includes the folowing people:
  • Mr. Martin J. Driscoll, Pres, CEO & Director (Age 60)
  • Dr. Radhakrishna P. Iyer, Co-Founder, Chief Scientific Officer & Director (Age 69)
  • Dr. Nezam H. Afdhal, Chief Medical Officer (Age 62)
  • Mr. Jonathan P. Freve CPA, CFO & Treasurer (Age 41)
  • Mr. Donald Mitchell MBA, VP of Operations & Corp. Devel.

When did Spring Bank Pharmaceuticals IPO?

(SBPH) raised $14 million in an initial public offering on Friday, May 6th 2016. The company issued 1,100,000 shares at $12.00-$14.00 per share. Dawson James Securities acted as the underwriter for the IPO.

How do I buy shares of Spring Bank Pharmaceuticals?

Shares of SBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Spring Bank Pharmaceuticals' stock price today?

One share of SBPH stock can currently be purchased for approximately $1.84.

How big of a company is Spring Bank Pharmaceuticals?

Spring Bank Pharmaceuticals has a market capitalization of $30.32 million. The company earns $-22,850,000.00 in net income (profit) each year or ($1.87) on an earnings per share basis. Spring Bank Pharmaceuticals employs 29 workers across the globe.View Additional Information About Spring Bank Pharmaceuticals.

What is Spring Bank Pharmaceuticals' official website?

The official website for Spring Bank Pharmaceuticals is http://springbankpharm.com/.

How can I contact Spring Bank Pharmaceuticals?

Spring Bank Pharmaceuticals' mailing address is 35 PARKWOOD DRIVE SUITE 210, HOPKINTON MA, 01748. The company can be reached via phone at 508-473-5993 or via email at [email protected]


MarketBeat Community Rating for Spring Bank Pharmaceuticals (NASDAQ SBPH)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  208 (Vote Outperform)
Underperform Votes:  234 (Vote Underperform)
Total Votes:  442
MarketBeat's community ratings are surveys of what our community members think about Spring Bank Pharmaceuticals and other stocks. Vote "Outperform" if you believe SBPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SBPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel